Observational study on Endometrial Stromal Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects both retrospective and prospective data on patients diagnosed with Endometrial Stromal Tumors (EST) to better understand the tumor's biology, natural history, and the effectiveness of various treatment options. The study involves reviewing patient records and treatment outcomes according to established disease guidelines and local practices. Additionally, a central expert pathologist will confirm the diagnosis to ensure accuracy in the data collected.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with a diagnosis of Endometrial Stromal Tumor (EST) according to the World Health Organization (WHO) classification 2003 or 2014
* Informed consent signature

Exclusion Criteria:

* patients with different diagnosis from EST

Where it's running

• Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Mi, Italy Recruiting
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST
  Meldola, Fc, Italy Not yet recruiting
• Istituto Europeo di Oncologia
  Milan, Mi, Italy Not yet recruiting
• Azienda Ospedaliera Universitaria Paolo Giaccone
  Palermo, PA, Italy Not yet recruiting
• Centro di Riferimento Oncologico di Aviano
  Aviano, Pd, Italy Not yet recruiting
• Istituto Oncologico Veneto
  Padova, Pd, Italy Not yet recruiting

Study contacts

• Study coordinator: Gianluca Ignazzi, PhD
• Email: gianluca.ignazzi@italiansarcomagroup.org
• Phone: +393335359192

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lurbinectedin plus irinotecan for advanced desmoplastic small round cell tumor

  This study will try lurbinectedin combined with irinotecan in people 15 and older whose desmoplastic small round cell tumor has come back or spread after anthracycline chemotherapy.

  Recruiting at 6 sites Phase 2 Italian Sarcoma Group · Candiolo, Torino and 10 other locations · NCT07328425

• Observational study of localized angiosarcoma

  This study is trying to find the best ways to treat localized angiosarcoma by looking at how patients are managed across different hospitals in Italy.

  Recruiting at 12 sites Italian Sarcoma Group · Rozzano, Milano and 18 other locations · NCT06375941

• Observational study of localized osteosarcoma characteristics and treatments

  This study is looking at the characteristics and treatments of people with localized osteosarcoma to see how well current therapies work and to help improve future care.

  Recruiting at 15 sites Italian Sarcoma Group · Aviano, Pordenone and 15 other locations · NCT04890067

• Observational study on Ewing's sarcoma of the bone

  This study is collecting information from patients with Ewing's sarcoma to learn more about the disease and improve treatment options.

  Recruiting at 17 sites Italian Sarcoma Group · Rozzano, MI and 18 other locations · NCT04845893

• Observational study on breast sarcoma characteristics and outcomes

  This study looks at the characteristics and treatment outcomes of patients with breast sarcoma to help improve care for this rare type of tumor.

  Recruiting Italian Sarcoma Group · Bologna, BO and 13 other locations · NCT04749446

• Evaluating Trabectedin for Advanced Leiomyosarcoma

  This study is testing if a drug called Trabectedin can help people with advanced leiomyosarcoma feel better and live longer compared to another treatment called Gemcitabine.

  Recruiting at 15 sites Phase 2 Italian Sarcoma Group · Bologna, BO and 16 other locations · NCT04383119

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.